TriNetX, a global health research network that claims to revolutionise clinical research and enable discoveries through the generation of real-world evidence, is collaborating with the FDA Sentinel Operations Center at the Harvard Pilgrim Health Care Institute (HPHCI), it was reported on Thursday.

The collaboration is aimed at monitoring priority drugs used for the care of hospitalised COVID-19 patients.

HPHCI is leveraging TriNetX's de-identified COVID-19 clinical data set to support studies that are intended to sequentially monitor sedatives and priority drugs used to assist with mechanical ventilation, therapies for respiratory disease, and other medications used to treat COVID-19. The aim of these projects is to evaluate changing patterns of use to support regional evaluations of drug use and to assess the possibilities of medicine shortages.

Jeffrey Brown, PhD, from the Department of Population Medicine at Harvard Medical School and the HPHCI, said, 'Rapid and interactive access to a large, growing, and frequently updated data source of COVID-19 patients is critical for monitoring drug use in these patients. TriNetX is providing the right data at the right time in a way that makes it easily available to decision makers.'